Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer

DISEASE CHARACTERISTICS:

* Histologically or cytologically confirmed small cell lung cancer (SCLC)

  * Must have received at least one prior course of standard chemotherapy and, if indicated, up to 6,900 cGy of thoracic radiotherapy
  * Patients who received prior radiotherapy must show evidence of progressive disease
  * Patients who received no prior radiotherapy to the primary tumor must show evidence of stable or progressive disease
* Measurable disease
* Must have evidence of carcinoembryonic antigen (CEA) production or expression documented by one of the following:

  * Serum CEA at least 10 ng/mL
  * Positive immunohistology of either the primary tumor or a metastasis with CEA specific monoclonal antibody
* Must have unilateral bone marrow biopsy with less than 25% tumor involvement
* No known, active brain metastases

PATIENT CHARACTERISTICS:

Age:

* 18 and over

Performance status:

* Karnofsky 70-100%
* ECOG 0-2

Life expectancy:

* At least 3 months

Hematopoietic:

* WBC at least 3,000/mm\^3
* Granulocyte count at least 1,500/mm\^3
* Platelet count at least 100,000/mm\^3

Hepatic:

* Bilirubin no greater than 2 mg/dL
* AST no greater than 2 times upper limit of normal (ULN)
* No hepatitis B or C
* No other serious liver abnormality

Renal:

* Creatinine no greater than 1.5 times ULN
* No urinary incontinence

Cardiovascular:

* Ejection fraction at least 50%

Pulmonary:

* FEV\_1 and FVC at least 60%
* DLCO at least 50% predicted

Other:

* No severe anorexia, nausea, or vomiting
* No other significant medical problems
* No prisoners
* No reactivity to humanized MN-14 (in patients with prior exposure to chimeric or humanized antibody)
* HIV negative
* No active HIV-related disease
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception during and for at least 3 months following study participation

PRIOR CONCURRENT THERAPY:

Biologic therapy:

* See Chemotherapy
* No concurrent growth factors (e.g., filgrastim \[G-CSF\])

Chemotherapy:

* See Disease Characteristics
* At least 4 weeks since prior chemotherapy
* No prior high dose chemotherapy with stem cell transplantation

Endocrine therapy:

* Not specified

Radiotherapy:

* See Disease Characteristics
* At least 4 weeks since prior radiotherapy
* Prior radiotherapy to less than 30% of red marrow (including standard chest x-ray for limited stage SCLC) allowed

Surgery:

* At least 4 weeks since prior major surgery